ArticleTransplantation and cellular therapy2022

A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.

Folashade Otegbeye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.